Manufacturing and Regulatory Strategies for Clinical AAV2-hRPE65

Current Gene Therapy

Volumn 10, Issue 5, 2010, Pages 341-349

  Wright, J Fraser ^a,b   Wellman, Jennifer ^a   High, Katherine A ^a,b,c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

AAV vectors; CGMP; Regulatory affairs

Indexed keywords

PARVOVIRUS VECTOR; PROTEIN; RETINAL PIGMENT EPITHELIAL ASSOCIATED PROTEIN 65; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; CLINICAL TRIAL (TOPIC); DRUG MANUFACTURE; GENE THERAPY; GENE TRANSFER; GOOD MANUFACTURING PRACTICE; HUMAN; LEBER CONGENITAL AMAUROSIS; NONHUMAN; REVIEW; VIRUS RECOMBINANT;

ADENO-ASSOCIATED VIRUS;

EID: 78651292759     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652310793180715     Document Type: Review

References (50)

1. den Hollander AI, Roepman R, Koenekoop RK, Cremers FP. Lebercongenital amaurosis: genes, proteins and disease mechanisms. Prog Retin Eye Res 2008; 27: 391-419.
2. Maguire AM, High KA, Auricchio A, et al. Age-dependent effectsof RPE65 gene therapy for Leber's congenital amaurosis: a phase 1dose-escalation trial. Lancet 2009; 374: 1597-605.
3. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy ofgene transfer for Leber's congenital amaurosis. N Engl J Med 2008; 358: 2240-8.
4. Simonelli F, Maguire AM, Testa F, et al. Gene therapy for Leber'scongenital amaurosis is safe and effective through 1.5 years aftervector administration. Mol Ther 2009; 18: 643-50.
5. Bennicelli J, Wright JF, Komaromy A, et al. Reversal of blindnessin animal models of leber congenital amaurosis using optimizedAAV2-mediated gene transfer. Mol Ther 2008; 16: 458-65.
6. Dejneka NS, Surace EM, Aleman TS, et al. In utero gene therapyrescues vision in a murine model of congenital blindness. Mol Ther 2004; 9: 182-8.
7. Acland GM, Aguirre GD, Bennett J, et al. Long-term restoration ofrod and cone vision by single dose rAAV-mediated gene transfer tothe retina in a canine model of childhood blindness. Mol Ther 2005; 12: 1072-82.
8. Acland GM, Aguirre GD, Ray J, et al. Gene therapy restores visionin a canine model of childhood blindness. Nat Genet 2001; 28: 92-5.
9. Nelson RM. Minimal risk, yet again. J Pediatr 2007; 150: 570-2.
10. Wendler D, Belsky L, Thompson KM, Emanuel EJ. Quantifyingthe federal minimal risk standard: implications for pediatricresearch without a prospect of direct benefit. JAMA 2005; 294: 826-32.
11. Jacobson SG, Aleman TS, Cideciyan AV, et al. Identifyingphotoreceptors in blind eyes caused by RPE65 mutations:Prerequisite for human gene therapy success. Proc Natl Acad Sci US A 2005; 102: 6177-82.
12. http://oba.od.nih.gov/rdna/rdna.html; Minutes of the Recombinant DNA Advisory Committee-12/13-14/05 (RAC_minutes_12-05. pdf). US Department of Health and Human Services, Recombinant DNA Advisory Committee 2005.
13. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction ofliver in hemophilia by AAV-Factor IX and limitations imposed bythe host immune response. Nat Med 2006; 12: 342-7.
14. McPhee SW, Janson CG, Li C, et al. Immune responses to AAV ina phase I study for Canavan disease. J Gene Med 2006; 8: 577-88.
15. Worgall S, Sondhi D, Hackett NR, et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther 2008; 19: 463-74.
16. Carter BJ. Adeno-associated virus vectors in clinical trials. Hum Gene Ther 2005; 16: 541-50.
17. Fiandaca M, Forsayeth J, Bankiewicz K. Current status of genetherapy trials for Parkinson's disease. Exp Neurol 2008; 209: 51-7.
18. Warrington KH, Jr., Herzog RW. Treatment of human disease byadeno-associated viral gene transfer. Hum Genet 2006; 119: 571-603.
19. http://www.access.gpo.gov/nara/cfr/index.html. 21CFR Parts 120and 211: Current Good Manufacturing Practice in manufacturing, processing, packing or holding of drugs; General and current Good Manufacturing Practice for finished pharmaceuticals.
20. http://www.fda.gov/cber/guidelines.htm. US Department Health Human Services, Food and Drug Administration, Center forBiologics Evaluation and Research. Guidance for FDA andSponsors: Content and review of Chemistry, Manufacturing, andControl (CMC)information for human gene therapy Investigational New Drug applications (INDs). 2004a.
21. http://www.fda.gov/cber/guidelines.htm. US Department of Healthand Human Services, Food and Drug Administration, Center forDrug Evaluation and Research, Center for Biologics Evaluationand Research, Center for Veterinary Medicine, Office ofRegulatory Affairs. Guidance for Industry: Quality Systemsapproach to pharmaceutical CGMP regulations. 2006b.
22. PDA Points to Consider for Aseptic Processing. PDA J Pharm Sci Technol 2003; 51: 1-72.
23. Mingozzi F, Maus MV, Hui DJ, et al. CD8(+) T-cell responses toadeno-associated virus capsid in humans. Nat Med 2007; 13: 419-22.
24. Grimm D, Kern A, Rittner K, Kleinschmidt JA. Novel tools forproduction and purification of recombinant adenoassociated virusvectors. Hum Gene Ther 1998; 9: 2745-60.
25. Matsushita T, Elliger S, Elliger C, et al. Adeno-associated virusvectors can be efficiently produced without helper virus. Gene Ther 1998; 5: 938-45.
26. Clark KR, Liu X, McGrath JP, Johnson PR. Highly purifiedrecombinant adeno-associated virus vectors are biologically activeand free of detectable helper and wild-type viruses. Hum Gene Ther 1999; 10: 1031-9.
27. Clark KR, Voulgaropoulou F, Fraley DM, Johnson PR. Cell linesfor the production of recombinant adeno-associated virus. Hum Gene Ther 1995; 6: 1329-41.
28. Conway JE, Rhys CM, Zolotukhin I, et al. High-titer recombinantadeno-associated virus production utilizing a recombinant herpessimplex virus type I vector expressing AAV-2 Rep and Cap. Gene Ther 1999; 6: 986-93.
29. Xiao X, Li J, Samulski RJ. Production of high-titer recombinantadeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224-32.
30. Negrete A, Yang LC, Mendez AF, Levy JR, Kotin RM. Economized large-scale production of high yield of rAAV for genetherapy applications exploiting baculovirus expression system. JGene Med 2007; 9: 938-48.
31. Urabe M, Ding C, Kotin RM. Insect cells as a factory to produceadeno-associated virus type 2 vectors. Hum Gene Ther 2002; 13: 1935-43.
32. http://www.fda.gov/cber/gdlns.virsafe.pdf. US Department Health Human Services, Food and Drug Administration. Internationalconference on harmonisation; Guidance on viral safety evaluationof biotechnology products derived from cell lines of human oranimal origin. Federal Register 1998.
33. Wright JF. Manufacturing and characterizing AAV-based vectorsfor use in clinical studies. Gene Ther 2008; 15: 840-8.
34. Allen JM, Debelak DJ, Reynolds TC, Miller AD. Identification andelimination of replication-competent adeno-associated virus (AAV)that can arise by nonhomologous recombination during AAVvector production. J Virol 1997; 71: 6816-22.
35. Muzyczka N. Use of adeno-associated virus as a generaltransduction vector for mammalian cells. Curr Top Microbiol Immunol 1992; 158: 97-129.
36. Samulski RJ, Chang LS, Shenk T. Helper-free stocks ofrecombinant adeno-associated viruses: normal integration does notrequire viral gene expression. J Virol 1989; 63: 3822-8.
37. Chadeuf G, Ciron C, Moullier P, Salvetti A. Evidence forencapsidation of prokaryotic sequences during recombinant adenoassociatedvirus production and their in vivo persistence aftervector delivery. Mol Ther 2005; 12: 744-53.
38. http://www.emea.europa.eu/pdfs/human/genetherapy/18398904en.pdf. Report from the CHMP gene therapy expert group meeting. European Medicines Agency 2005; EMEA/CHMP/183989/202005.
39. Smith PH, Wright JF, Qu G, et al. Packaging of host cell andplasmid DNA into recombinant adeno-associated virus producedby triple transfection. Mol Ther 2003; 7: S348.
40. Hauck B, Murphy SL, Smith PH, et al. Undetectable transcriptionof cap in a clinical AAV vector: implications for preformed capsidin immune responses. Mol Ther 2009; 17: 144-52.
41. World Health Organization. Requirements for the use of animalcells as in vitro substrates for the production of biologicals(Requirement for Biological substance No. 50). WHO Expert Committee on Biological Standardization Geneva, World Health Organization, 1998, Annex 1 (WHO Technical Report Series, No878) 1998.
42. Pien GC, Basner-Tschakarjan E, Hui DJ, et al. Capsid antigenpresentation flags human hepatocytes for destruction aftertransduction by adeno-associated viral vectors. J Clin Invest 2009; 119: 1688-95.
43. Belter PA, Cussler CL, Hu WS. Bioseparations. John Wiley andSons, New York 1988.
44. Sadana A. Bioseparation of proteins. Academic Press, New York 1998.
45. Qu G, Bahr-Davidson J, Prado J, et al. Separation of adenoassociatedvirus type 2 empty particles from genome containingvectors by anion-exchange column chromatography. J Virol Methods 2007; 140: 183-92.
46. Wright JF, Le T, Prado J, et al. Identification of factors thatcontribute to recombinant AAV2 particle aggregation and methodsto prevent its occurrence during vector purification andformulation. Mol Ther 2005; 12: 171-8.
47. http://www.fda.gov/cber/guidelines.htm. US Department Health Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation andResearch. Guidance for Industry: Container closure systems forpackaging human drugs and biologics. 1999.
48. http://www.fda.gov/cber/guidelines.htm. US Department Health Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation andResearch, Office of Regulatory Affairs. Guidance for Industry:Sterile drug products produced by aseptic processing-Currentgood manufacturing practice. 2004b.
49. Gombold J, Peden K, Gavin D, et al. Lot release andcharacterization testing of live-virus-based vaccines and genetherapy products, Part 1: Factors influencing assay choices. Bioprocess Int 2006; 4: 46-56.
50. http://www.fda.gov/cber/guidelines.htm. US Department Health Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation andResearch. Guidance for Industry: Q1A (R2) Stability testing of newdrug substances and products. 2003b.